- Home
- CISS vs VRAX Comparison
CISS vs VRAX Comparison
Compare CISS & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | VRAX |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | Greece | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 2.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CISS | VRAX |
|---|---|---|
| Price | $0.22 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 1.7M | ★ 15.4M |
| Earning Date | 11-18-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,613,149.00 | $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $0.35 |
| 52 Week High | $11.52 | $3.20 |
Technical Indicators
Market Signals| Indicator | CISS | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 16.93 | 36.54 |
| Support Level | $0.21 | $0.35 |
| Resistance Level | $0.24 | $0.43 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 0.86 | 0.10 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).